Comparative Pharmacology
Head-to-head clinical analysis: PRILOSEC OTC versus PROTONIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRILOSEC OTC versus PROTONIX.
PRILOSEC OTC vs PROTONIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, suppressing gastric acid secretion.
Proton pump inhibitor that inhibits the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of gastric acid secretion.
20 mg orally once daily for 14 days for frequent heartburn; may repeat 14-day course every 4 months.
40 mg orally once daily; alternatively, 40 mg IV once daily for 7-10 days.
None Documented
None Documented
Approximately 0.5–1 hour in healthy subjects; longer (up to 3 hours) in slow metabolizers or hepatic impairment. Clinically, the duration of acid suppression exceeds the half-life due to accumulation in parietal cell canaliculi.
Terminal elimination half-life is about 1–2 hours in healthy individuals; in CYP2C19 poor metabolizers or hepatic impairment, half-life may increase up to 3–6 hours, but clinical impact is minimal due to irreversible binding to H+/K+-ATPase.
Primarily hepatic metabolism; about 80% of metabolites are excreted in urine, and the remainder in feces via bile. Less than 1% of unchanged drug is excreted in urine.
Approximately 80% of a dose is excreted as metabolites in urine, with the remainder (≈20%) in feces via biliary elimination.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor